reported that R-2HG displayed anti-tumor activity in leukemia and glioma through targeting FTO, leading to MYC mRNA decay and downregulation of MYC/CEBPA-associated oncogenic pathways (46). This evidence concerns the gene CEBPA and neoplasm.